TransCode and Quantum Leap seek FDA approval for Phase IIa TTX-MC138 trial
The Phase IIa clinical trial is scheduled to begin in the first half of 2026.
Analysis
View MoreAPIs to the rescue?
Oral bioavailability remains one of the biggest challenges in drug development, particularly for small-molecule APIs with poor solubility or permeability. Liam Critchley explores how pharmaceutical companies are using integrated formulation...
AI now: What QbD and PAT missed
Cool heads, smart chains
Sustainability vs suitability
Integrating sustainability compliance